Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679788 | 0.82 | LTA4H (0.50) | ALDH1A1 | |
| SCHEMBL4970580 | 0.82 | MAOB (0.50) | MAOBALDH1A1KDM4EHSD17B10KMT2A | |
| SCHEMBL28949610 | 0.82 | LTA4H (0.50) | ALDH1A1 | |
| SCHEMBL1591503 | 0.80 | TSHR (0.65) | TSHRMAOBALDH1A1KDM4ESMPD1 | |
| SCHEMBL1590940 | 0.80 | TSHR (0.65) | TSHRMAOBALDH1A1KDM4ESMPD1 | |
| SCHEMBL13828553 | 0.80 | TSHR (0.65) | TSHRMAOBALDH1A1KDM4ESMPD1 | |
| SCHEMBL2623452 | 0.80 | TSHR (0.65) | TSHRMAOBALDH1A1KDM4ESMPD1 | |
| SCHEMBL6686112 | 0.80 | LMNA (0.52) | ALDH1A1CYP2D6 | |
| SCHEMBL3683494 | 0.80 | TSHR (0.65) | TSHRMAOBALDH1A1KDM4ESMPD1 | |
| SCHEMBL28730788 | 0.79 | LTA4H (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710073-B2 | Anti-infective derivatives, method for the production thereof, pharmaceutical compositions containing same and uses of said derivatives in treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2014-04-29 | — | — | US | disclosed |
| US-20110092536-A1 | NOVEL ANTI-INFECTIOUS DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES OF SAID DERIVATIVES IN TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFOQUE (C.N. (FR) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092536-A1 | NOVEL ANTI-INFECTIOUS DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES OF SAID DERIVATIVES IN TREATMENT | DHFR, COASY, QDPR | TSHR 3057/4885MAOB 286/4885ALDH1A1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.